Seegene awarded patent in the U.S. and Europe for Annealing Control Primer

Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded patent in the U.S. and Europe for Annealing Control Primer (ACP), a new technology for amplifying a specific region of a gene with much higher specificity and reproducibility than conventional approaches.

The success of PCR gene amplification rests on the specificity with which a primer anneals, or binds, to nucleic acids. The major limitation of primers in use today is that the high rate with which they anneal to non-specific targets and fail to distinguish target nucleic acids, leading to false positive test results. Therefore, there is an urgent need in the diagnostics testing community for a primer that greatly improves annealing specificity to generate true test results.